Mus vs New Zealand: Treatment success rate for patients treated for MDR-TB
Mus
100.0%
in 2022
New Zealand
100.0%
in 2022
Mus rank
1st
New Zealand rank
1st
Treatment success rate for patients treated for MDR-TB over time
- Mus
- New Zealand
How they compare
Mus currently reports 100.0% against 100.0% in New Zealand, a difference of 0.0%.
The two have swapped places 3 times across 12 shared years of data; in 2007 it was Mus ahead.
Mus ranks 1st and New Zealand ranks 1st of 1 regions.
Across the 3 decades both report, Mus averaged higher in 1 and New Zealand in 2.
Head to head by decade
| Decade | Mus | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 100.0% | 46.5% | 53.5% | Mus |
| 2010s | 64.6% | 67.6% | 3.0% | New Zealand |
| 2020s | 75.0% | 100.0% | 25.0% | New Zealand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, Mus or New Zealand?
- Mus, at 100.0% against 100.0% in New Zealand as of 2022.
- What is the difference in treatment success rate for patients treated for mdr-tb between Mus and New Zealand?
- 0.0%, with Mus ahead.
- How many years of comparable data are there for Mus and New Zealand?
- 12 years are reported by both, from 2007 to 2022.
- How do Mus and New Zealand rank globally for treatment success rate for patients treated for mdr-tb?
- Mus ranks 1st and New Zealand ranks 1st of 1 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.